Studies leading up to the FDA approval found that people with hand eczema who used the cream were more likely to improve than ...

The FDA approved Anzupgo for the treatment of moderate to severe chronic hand eczema in adults who do not adequately respond ...

The first therapy specifically indicated for chronic hand eczema (CHE) has passed muster at the FDA.

Adult patients with moderate to severe hand eczema with previous treatment failure or in whom topical corticosteroids are ...

The FDA has approved a new treatment, sold under the name Anzupgo and containing a drug called delgocitinib, as the first skin cream for adults with long-term or chronic hand eczema (CHE), which ...

Danish dermatology specialist Leo Pharma has scored an FDA approval that makes its JAK inhibitor cream Anzupgo (del | Despite chronic hand eczema affecting 1 in 10 people worldwide, there was no ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

LEO Pharma’s Anzupgo (delgocitinib) cream has been approved by the US Food and Drug Administration (FDA) to treat adults with ...

The topical JAK inhibitor is the first treatment approved specifically for adults with moderate-to-severe chronic hand eczema.

Chronic hand eczema is a common dermatological condition that presents itself as hand dermatitis which lasts over 3 months or recurs at least twice a year. 2 Genetic predispositions, ...

“Chronic hand eczema is an heterogenous disease with significant interpatient variability in Th1, Th2, Th17 and Th22 activation,” Robert Bissonnette, MD, ...